Search

Displaying results 311 - 320 of 536 in total
  1. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    [L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD).

  2. Drug

    Linerixibat

    go.drugbank.com/drugs/DB11729
    ApprovedInvestigational

    [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

  3. Drug

    Gepotidacin

    go.drugbank.com/drugs/DB12134
    ApprovedInvestigational

    [L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.

  4. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [A253248] First approved by the FDA on March 27, 2017,[A253912] niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  5. Indication

    Mucocutaneous Leishmaniasis

    go.drugbank.com/conditions/DBCOND0051127
    Drugs: Amphotericin B · Miltefosine · Sodium stibogluconate
    Synonyms: Leishmania braziliensis complex
  6. Drug

    Zinc oxide

    go.drugbank.com/drugs/DB09321
    ApprovedInvestigational

    Zinc oxide is an inorganic compound used in a number of manufacturing processes. It can be found in rubbers, plastics, ceramics, glass, cement, lubricants, paints, ointments, adhesives, sealants, pigments, foods, batteries, ferrites, fir...

    Mixtures: Sente Daily Repair Complex SPF 30, Sudden Change Derma Renewal ComplexProducts: ZINCO OSSIDO MARCO VITI, MARA Algae Zinc Sea Kale Sunscreen Serum SPF 30
  7. Drug

    Brolamfetamine

    go.drugbank.com/drugs/DB01484
    ExperimentalIllicit

    Categories: Amphetamines
  8. Indication

    Wilson's Disease

    go.drugbank.com/conditions/DBCOND0032702
    Drugs: Penicillamine · Triethylenetetramine · Zinc
    Synonyms: Copper storage disease, Iron &/or copper &/or magnesium disorder (& [haemochromatosis] or [Wilson's disease])
  9. Drug

    Lutetium Lu-177 vipivotide tetraxetan

    go.drugbank.com/drugs/DB16778
    ApprovedInvestigational

    [L41280] Lutetium Lu-177 vipivotide tetraxetan was first approved by the FDA on March 23, 2022 as a treatment for prostate-specific membrane antigen–positive metastatic castration-resistant prostate

  10. Drug

    Respiratory syncytial virus vaccine, adjuvanted

    go.drugbank.com/drugs/DB17762
    ApprovedInvestigational

    [L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380]